Abstract: In a process for the preparation of ring compounds via a combinatorial synthesis, the reaction procedure is based on a Suzuki coupling, subsequent halo-demetallation and finally a further Suzuki coupling. The Suzuki couplings are each carried out with a boronic acid or a boronic acid ester. The reaction procedure uses provides novel ring compounds and uses novel synthesis units used for this purpose. The novel ring compounds are suitable for use as constituents in liquid-crystalline mixtures.

Abstract: Compounds according to formula (I): wherein R1, R2, R3, n and X are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity. Additionally, compounds according to Formula III: wherein Z, R?1, and R?2 are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful as intermediates for production of compounds that modulate CCR5 chemokine receptor activity.

Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Abstract: A process for separating a feed F by simulated moving bed adsorption in a SMB device comprises external bypass lines Li/i+1 which directly connect two successive plates, Pi, Pi+1, the index “i” being either even or (exclusive of the foregoing) odd, along the whole length of the column, allowing said plates to be flushed, in which each of the bypass lines Li/i+1 comprises automated means for regulating the flow rate in the bypass lines, the bypass lines in certain cases being subject to a flushing flow during injection or withdrawal operations.

Abstract: An organic semiconducting layer formulation containing an organic binder which has a permittivity, ?, at 1,000 Hz of 3.3 or less and a polyacene compound of Formula A: and processes for the preparation thereof and uses thereof in various electronic devices.

Abstract: The invention relates to a birefringent layer having negative optical dispersion, a liquid crystal (LC) medium for its preparation, and the use of the birefringent layer and the LC media in optical, electrooptical, electronic, semiconducting or luminescent components or devices.

Abstract: Novel triazole derivatives of the formula (I) in which R1-R6 and Y have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

Abstract: Novel compounds of the formula I (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R, Q, W, X and Z have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.

Abstract: The invention relates to novel mono-, oligo and polymers of thieno[2,3-b]thiophene, to their use as semiconductors or charge transport materials, in optical, electro-optical or electronic devices like LCDs, optical films, FETs or OFETs for TFT-LCDs and IC devices such as RFID tags, electroluminescent devices in flat panel displays or photovoltaic or sensor devices, and further relates to a FET, light emitting device or ID tag comprising the novel polymers.

Abstract: The present invention relates to pearlescent pigments based on flake-form substrates which have at least one FeOOH layer and at least one TiO2 layer or at least one TiO2/SiO2/TiO2 layer package, and to the use thereof, inter alia, in paints, coatings, printing inks, powder coatings, plastics and in particular in care and decorative cosmetics.

Abstract: As a compound having a potent oral activity and a long-lasting cysLT1/cysLT2 receptor antagonistic activity, the compound of the formula (I): which exhibits potent antagonistic activity against the cysLT1/cysLT2 receptor, and have long-lasting effects even in case of oral administration, and therefore is useful as an oral agent for preventing and/or treating a variety of diseases, for example, respiratory disease (for example, asthma (bronchial asthma, etc.), chronic obstructive pulmonary disease (COPD), pulmonary emphysema, chronic bronchitis, pneumonia (interstitial pneumonia, etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), apnea syndrome, allergic rhinitis, sinusitis (acute sinusitis, chronic sinusitis, etc.), pulmonary fibrosis, coughing (chronic coughing, etc.), and the like) was developed.

Abstract: The invention relates to a novel catalyst having excellent activity and selectivity for reducing nitric oxides (NO/NO2) to nitrogen gas (N2) with hydrogen (H2) being used as a reducing agent under strongly oxidizing conditions (e.g., 2-10 vol % O2) (H2-SCR) in the 100-400° C. range, but in particular to the low-temperature range 100-200° C. The inventive catalyst is a combination of platinum and palladium which are in contact with solid phases of a mixed MgO and CeO2 medium.

Abstract: The present invention relates to a liquid-crystal (LC) display of the PSA (polymer sustained alignment) type, and to novel polymerisable compounds and novel LC media for use in PSA displays.

Abstract: The invention relates to compounds of the formula (I), in which Ar denotes a mono- or bicyclic aromatic homo- or heterocycle having 1 to 4 N, O and/or S atoms and 5 to 10 skeleton atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, Hal, A, OH, OA, NH2, NHA, NA2, NO2, CN, OCN, SCN, COOH, COOA, CONH2, CONHA, CONA2, NHCOA, NHCONH2, NHSO2A, CHO, COA, SO2NH2 and/or S(O)9A, A denotes unbranched, branched or cyclic alkyl having 1-14 C atoms, in which one or two CH2 groups may be replaced by O or S atoms and/or by —CH?CH— groups and/or in addition 1-7 H atoms may be replaced by F and/or Cl, Hal: F, Cl, Br or I, D: NH, NH2, NA2, NHA, CH2, CH3, OH, OA, O or S, E: CH2, CH, NH or N, Y: E or a saturated or unsaturated bond, X: CH2, O or NH, Q: Hal, A, OH, OA, NH2, NHA, NA2, NO2, CN, OCN, SCN, COOH, COOA, CONH2, CONHA, CONA2, NHCOA, NHCONH2, NHSO2A, CHO, COA, SO2NH2 or X-M, to the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular t

Abstract: The invention relates to a process for the treatment of heavy petroleum feedstocks in order to produce a gas oil fraction having a sulphur content of less than 50 ppm and generally 10 ppm which comprises the following stages: e) mild hydrocracking in a catalyst fixed bed, f) separation of the hydrogen sulphide, of a distillate cut including a gas oil fraction and of a fraction which is heavier than the gas oil, g) hydrotreating, by contact with at least one catalyst, of at least a portion of the distillate cut obtained in stage b) including the gas oil fraction, as a mixture with a feedstock resulting from a crude or refined renewable source, h) separation of a gas oil cut comprising less than 50 ppm of sulphur. Advantageously, the heavy fraction is sent for catalytic cracking. Preferably, the process is carried out with makeup hydrogen introduced in stage c) and very advantageously all the makeup hydrogen for the process is introduced in stage c).

Abstract: Different papers known in prior art develop only moderate resistance to fats or contain fluorocarbon compounds or chromium complexes in the mass or in an impregnating liquor in order to develop great fat and oil penetration resistance. Said fluoride or chromium compounds represent substances that are known to be or at least seriously suspected of being unhealthy. Hence, the aim of the invention is to create a paper that is free from unhealthy components while being provided with great fat and oil penetration resistance, being easy to print, and being recyclable.

Abstract: Compounds of the formula I, in which s, k, I, W, R1, R2, R3, and U have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.

Abstract: This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.

Abstract: The invention relates to an indexable insert of hard metal or cermet with a multi-layer surface coating for a machining of objects essentially made of metal or an alloy, in particular those of a polyphase material such as casting alloys and the like. To increase the service life of the tools with optionally improved machining surface, it is provided with a multi-layer coating that the outermost layer or cover layer is formed as an oxide layer, in particular of ?-Al2O3, whereby the layer beneath the cover layer and connected threto is composed of TiN.

Abstract: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which act as ligands for the ?7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.